Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18318354 | 0.94 | FDPS (0.42) | NAMPTEPHX2CHRNA7FDPSROCK1 | |
| SCHEMBL18318337 | 0.88 | CHRNA7 (0.43) | NAMPTEPHX2CHRNA7FDPSPRMT3 | |
| SCHEMBL18318448 | 0.88 | JUN (0.44) | EPHX2CHRNA7FDPSPRMT3MMP1 | |
| SCHEMBL18318839 | 0.87 | EPHX2 (0.45) | EPHX2CHRNA7FDPSPRMT3MMP1 | |
| SCHEMBL18318388 | 0.86 | FDPS (0.41) | EPHX2CHRNA7FDPSROCK1ACACB | |
| SCHEMBL18318344 | 0.85 | PIK3CD (0.45) | NAMPTPRMT3 | |
| SCHEMBL18319103 | 0.85 | CHEK2 (0.43) | FDPSROCK1PRMT3CHEK2 | |
| SCHEMBL18318040 | 0.85 | CHRNA7 (0.43) | EPHX2CHRNA7FDPSPRMT3MMP1 | |
| SCHEMBL18318731 | 0.84 | CHRNA7 (0.42) | NAMPTEPHX2CHRNA7FDPSPRMT3 | |
| SCHEMBL18319501 | 0.82 | LMNA (0.48) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | claimed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | claimed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | claimed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | claimed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | claimed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | claimed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | claimed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | claimed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | claimed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | claimed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | NAMPT 491/4885EPHX2 1352/4885CHRNA7 4048/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | NAMPT 475/4885EPHX2 1374/4885CHRNA7 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.